
LH Stock Forecast & Price Target
LH Analyst Ratings
Bulls say
Labcorp Holdings has demonstrated robust revenue growth, with Central Lab revenue increasing by 7.5% to reach $554.7 million, bolstered by notable trial wins and advancements in digital pathology capabilities. The company maintains a strong backlog of $8.71 billion, reflecting a year-over-year growth of approximately 10%, along with a trailing twelve-month net book-to-bill ratio of 1.11, indicating effective management of new business and client retention. Additionally, the Diagnostic segment reported revenue of $2.75 billion, marking an 8.9% year-over-year gain driven equally by organic growth and acquisitions, demonstrating Labcorp's resilience and strategic positioning in the competitive independent lab market.
Bears say
Labcorp Holdings faces several fundamental risks that contribute to a negative outlook on its stock, including adverse reimbursement changes under the Protecting Access to Medicare Act (PAMA) and challenges related to poor acquisition integration. The company is also under pressure from increasing competition within the clinical laboratory sector, which could hinder its market position, and economic uncertainty that may affect demand for its services. Additionally, potential regulatory challenges concerning laboratory-developed tests (LDTs) add further risk to its operational stability and financial performance.
This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
LH Analyst Forecast & Price Prediction
Start investing in LH
Order type
Buy in
Order amount
Est. shares
0 shares